BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?

BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-...

Descripción completa

Detalles Bibliográficos
Autores principales: Herr, Ricarda, Brummer, Tilman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905336/
https://www.ncbi.nlm.nih.gov/pubmed/27308494
http://dx.doi.org/10.1080/23723556.2014.1002709
Descripción
Sumario:BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-cell adhesion and differentiation, underlining a potential benefit of BRAF inhibitors in CRC.

Ejemplares similares